Physician profile
Oladele Oladapo
NPI 1750724886
$1,138.85
in general payments reported to CMS, 2019-2025
17 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $38.32 · 2021: $55.29 · 2022: $92.60 · 2023: $326 · 2024: $275 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.09 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $239.56 | 2019-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $150.84 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $123.18 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $95.75 | 2022-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.12 | 2022-2023 | |
| Axsome Therapeutics, INC. | $77.54 | 2023-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $75.34 | 2020-2021 | |
| Allergan, INC. | $65.82 | 2019 | |
| Indivior INC. | $53.75 | 2019-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $52.49 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Avanir Pharmaceuticals, INC. | $17.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.71 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $16.74 | 2024 | Trintellix |
| Tris Pharma INC | $16.64 | 2024 | Dyanavel Xr |
| Corium, LLC | $16.27 | 2024 | Azstarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.83 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oladele Oladapo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.